If the hepatitis B surface antibody (anti-HBs) is negative, does the person have immunity to hepatitis B?

Negative Hepatitis B Surface Antibody Does NOT Guarantee Immunity

A negative anti-HBs test means the person does NOT have detectable antibody-mediated immunity to hepatitis B and should be considered susceptible to HBV infection 1.

Understanding Anti-HBs and Immunity

The hepatitis B surface antibody (anti-HBs) is the primary marker used to determine immunity to hepatitis B. According to ACIP guidelines:

• Anti-HBs ≥10 mIU/mL = Immune and protected 1
• Anti-HBs <10 mIU/mL = NOT immune and susceptible to infection 1

When anti-HBs is negative (<10 mIU/mL), persons should be considered susceptible to HBV infection and counseled about precautions to prevent infection, including the need for HBIG postexposure prophylaxis if exposed to an HBsAg-positive source 1.

Clinical Context Matters

For Previously Vaccinated Individuals:

If someone completed the hepatitis B vaccine series but has negative anti-HBs:

• They are vaccine non-responders and require revaccination 1
• After revaccination with a complete second series, retest anti-HBs 1-2 months after the final dose 1
• If still negative after two complete vaccine series, test for HBsAg to rule out chronic infection 1
• These individuals remain susceptible and need postexposure prophylaxis with HBIG if exposed 1

For Immunocompetent Persons Who Previously Responded:

There is one important caveat: Immunocompetent persons who achieved anti-HBs ≥10 mIU/mL after completing the primary vaccine series are considered to have long-term protection, even if anti-HBs levels subsequently decline below 10 mIU/mL or become undetectable 1. This is due to immune memory.

However, this protection only applies if:

• There is documented evidence of anti-HBs ≥10 mIU/mL measured 1-2 months after completing the vaccine series 1
• The person is immunocompetent (not immunocompromised) 1

For Immunocompromised Persons:

The rules are different:

• Immunocompromised individuals (HIV-positive, hemodialysis patients, chemotherapy recipients, transplant recipients) may need annual anti-HBs testing 1
• If anti-HBs falls below 10 mIU/mL, they may need revaccination 1
• Anti-HBs >100 IU/L may offer better protection during immunosuppression, though effectiveness can be reduced with B-cell depleting therapies 2, 3

Special Considerations for HBsAg-Negative/Anti-HBc-Positive Individuals

For persons with resolved HBV infection (HBsAg-negative, anti-HBc-positive):

• High anti-HBs levels (>100 IU/L) appear protective against HBV reactivation during immunosuppression 2, 3
• Negative or low anti-HBs increases reactivation risk during immunosuppressive therapy 2, 3
• The 2025 EASL guidelines note that anti-HBs status can help stratify reactivation risk, particularly with corticosteroids at ultra-high doses 2

Common Pitfalls to Avoid

1. Don't assume immunity without documentation: Testing negative for anti-HBs years after vaccination doesn't necessarily mean the person was never immune—they may have had a protective response that waned. Check for documented post-vaccination testing 1.

2. Don't confuse detection methods: Some research suggests that very low-level antibodies below commercial assay detection limits may exist 4, but clinically, we use the ≥10 mIU/mL threshold as the standard for protection 1.

3. Beware of passively acquired antibody: Recent blood product transfusions can result in detectable anti-HBs that does NOT confer immunity 5. Always consider recent transfusion history.

4. Don't test at the wrong time: Anti-HBs testing is only meaningful 1-2 months after completing the vaccine series 1. Testing before completion of the series is not interpretable.

Practical Algorithm

If anti-HBs is negative:

1. Check vaccination history

   • If never vaccinated → Vaccinate with complete series
   • If vaccination history unknown → Consider prevaccination testing (anti-HBc, HBsAg, anti-HBs), then vaccinate

2. If previously vaccinated but no documented post-vaccination testing

   • Revaccinate with one dose, then retest 1-2 months later
   • If still <10 mIU/mL → Complete second full series, retest 1-2 months after final dose

3. If documented adequate response (≥10 mIU/mL) after prior vaccination

   • If immunocompetent → No action needed (immune memory protects)
   • If immunocompromised → Consider revaccination

4. If negative after two complete vaccine series

   • Test for HBsAg to rule out chronic infection
   • If HBsAg-negative → Counsel as susceptible, use HBIG for postexposure prophylaxis

The bottom line: A negative anti-HBs result means no detectable antibody immunity at that moment, and without documented prior adequate response, the person should be managed as susceptible to HBV infection.